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The immune system is a complex collection of cells, tissues, and chemical 
mediators positioned throughout the body, whose primary purpose is to protect 
us against infection. However, its function is not only fundamental in protection 
from infectious disease but also provides aberrant response in allergens such as with 
asthma and allergic rhinitis. Allergic diseases like asthma and allergic rhinitis are 
characterized by a distinct type of inflammatory response, driven by immunoglob-
ulin E (IgE)-dependent mechanisms. In asthma and allergic rhinitis, the inflam-
matory response is mediated by interaction of several immune cells (monocytes, 
lymphocytes, and polymorphonuclear cells) and cellular chemical mediators. In 
particular, atopic allergic response leads to destruction of multiple target cells such 
as epithelial, parenchymal and vascular and connective tissue of the airways. In 
addition, in inflammatory response in asthma and allergic rhinitis, sensory nerves 
are sensitized, leading to clinical manifestations. Sneezing and coughing are hyper-
sensitivity responses of sensory nerves in allergic rhinitis and asthma, respectively. 
Similarly, nasal congestion and discharge in allergic rhinitis are due to vasodilata-
tion that leads to plasma exudates as well as mucous secretion. The allergic inflam-
matory response is regulated by several transcription factors, particularly nuclear 
factor-κb (NF-κB), GATA-3 protein 3, and GATA binding protein.
Keywords: immunology, asthma and allergic rhinitis,, TH2 high, TH2 low, IL2 cells, 
Clara cell secretory protein (CC16), thymic stromal lymphopoietin (TSLP), interleukin 
(IL)-33, phenotypes, endotypes, united airway hypothesis, biological agents
1. Introduction
Allergic responses are mediated by IgE, a type of antibody associated with mast 
cells and basophils [1, 2]. Allergic rhinitis (i.e., inflammation of epithelia of nostril) 
is a reaction to allergens in the environment such as dust, pollen grain, and animal 
dander, among others. Patients with allergic rhinitis often present with congestion 
and inflammation (i.e., pain, reddening, and swelling) of the mucous membranes 
of the upper respiratory tract (nose, throat, eyes, and ears). In contrast, asthma 
is a complex heterogeneous syndrome characterized by increased inflammatory 
cells, airway hyper-reactivity (AHR), and structural changes in the lung [3]. The 
histological features of asthma include edema, cellular infiltration (typically with 
a prominent T lymphocyte and an eosinophil component), and sub-basement 
membrane collagen deposition.
Asthma is defined according to the Global Initiative for Asthma (GINA) 2018 
as a heterogeneous disease, usually characterized by chronic airway inflammation. 
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Asthma is induced by an inflammatory response against usually manageable 
environmental inorganic and organic compounds in the respiratory tract. Indeed, 
asthma attacks can be triggered by exercise, viral illness, and allergens such as 
pollen. Other triggers include medications, extremes of weather, stress, smoke, 
and certain foods. Key indicators include a history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness, and cough that vary over time and in 
intensity, together with variable expiratory airflow limitation. It has variations in 
severity, natural history, and response to therapy [4].
Patients diagnosed with atopy have an increased likelihood to allergic 
responses mediated via IgE, mast cells, and CD4+ lymphocytes. In atopy, the 
allergic inflammatory responses are mainly due to cytokines (interleukins (IL-3, 
IL-4, and IL-5)) released from CD4+ lymphocytes. The interleukins increase the 
IgE production to neutralize the allergens. However, the binding of IgE-allergen 
complex formed further induces de novo synthesis and release of vasoactive 
substances that exacerbate the inflammatory reaction. This allergic inflamma-
tory response occurs in two stages (early and late response) in both asthma and 
allergic rhinitis.
The allergic immune response recognizes allergens via germ line or random 
encoding, which can be innate and adaptive. The innate allergic immune responses 
are the first line of defense against allergens that use germ-line encoding and phago-
cytic cells. In contrast, the adaptive allergic response is mainly designed against 
infection and allergenic proteins from weed and pollen.
1.1 Pathogenesis of allergic rhinitis and asthma
According to the World Health Organization (WHO), the burden of asthma is 
estimated to have 300 million cases worldwide, making it one of the commonest 
noncommunicable diseases. Asthma is a serious global health problem affecting all 
age groups, with increasing prevalence in developing countries, treatment costs, 
and a burden for patients and the community. The WHO ranks asthma the highest 
among chronic illnesses afflicting the pediatric population worldwide. Of concern is 
that the majority of case fatalities attributed to asthma occur among populations in 
underdeveloped countries characterized with weak health systems for control and 
management of the disease [4–7].
Whereas allergic rhinitis results from activation of mucosal mast cells, asthma is 
triggered by allergen activation of submucosal mast cells in the lower airways. The 
nature and development airway inflammation may be driven by numerous factors, 
including pathogenic infections, pollution, or even relatively innocuous inhaled 
particles, such as allergens. International guidelines are available for the manage-
ment of severe asthma by the European Respiratory Society and the American 
Thoracic Society [6].
Chronic allergen exposure leads to the continuous presence of increased 
number of lymphocytes, eosinophils, neutrophils, basophils, and other leukocytes 
causing airway hyper-reactivity and remodeling—a thickening of the airway walls 
due to hyperplasia and hypertrophy of the smooth muscle layer, with the eventual 
development of fibrosis.
It has become apparent that there are many phenotypic and endotype types of 
asthma. In patients with allergic asthma endotypes, allergen can cause activation 
of mast cells in an antigen-specific manner. Also allergens can stimulate the airway 
epithelium, through toll-like receptors (TLRs) and other damage receptors, to 
release IL-25, IL33, and thymic stromal lymphopoietin (TSLP). These cytokines can 
lead to the activation of submucosal type two innate lymphoid cells (ILC2), induc-
ing these to release IL-4, IL-5, IL-9, and IL-13.
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2. Methodology
A comprehensive review of all aspects of immunology, components of the 
immune system, immune responses to asthma and allergic rhinitis in children and 
adults, and airway epithelial cell mucosal immunology was done in a systematic 
and explicit search of PubMed and HINARI—identifying, selecting, and criti-
cally appraising relevant research and textbooks of Immunology from Europe and 
the United States of America used in undergraduate and postgraduate Medical 
Education (Cochrane Collaboration) [7–9].
3. Results/findings
Critical analysis of scientific concepts in pulmonary immune inflammation of 
asthma and allergic rhinitis and an analysis of similarities, differences, and interac-
tions between these two diseases are done.
Knowledge of our immune system functions is critical in understanding 
allergic airway disease development as well as for selection of appropriate diag-
nostic and therapeutic options for patients with asthma and allergic rhinitis. A 
robust inflammatory response is essential to control asthma and allergic rhinitis, 
and both active and innate mechanisms of immunity are important in this regard. 
The failure of resolution or persistent pro-inflammatory immune responses 
results in chronic inflammatory airway diseases like asthma and allergic rhinitis. 
It is also becoming increasingly important to phenotype airway inflammation in 
individual patients to allow targeted treatment as we move toward personalized 
therapies for asthma.
The majority of patients of asthma suffer from an allergic variant of the dis-
ease that is triggered by an IgE-driven immune response directed against inhaled 
antigens and leads to various symptoms, such as wheezing, coughing, and breathing 
difficulties. The immunopathogenesis of allergic asthma involves a complex inter-
play between the immune system and parenchymal cells of the lung, including the 
airway epithelium [10, 11].
Inhaled allergens are phagocytosed by macrophages and dendritic cells (DCs) 
presented on major histocompatibility complex (MHC) class II molecules and initi-
ate the differentiation of Th2 cells and a humoral immune response. Following class 
switching, Ag-specific B cells secrete immunoglobulin E which causes degranula-
tion of mast cells.
Cytokines, such as IL-4, IL-5, and IL-13, are produced by TH2 cells, mast cells, 
basophils, and type 2 innate lymphoid cells, as well as airway epithelial cells, and 
they trigger pathological events, including airway wall remodeling, bronchial 
hyper responsiveness, and goblet cell metaplasia. Once the immune response has 
been initiated, eosinophils become the major effector cells that are responsible 
for airway dysfunction. In addition to the importance of immune cells in allergic 
asthma, there is evidence for a prominent role of airway epithelial cells in this 
disease (Table 1).
3.1 The innate inflammatory immune response and asthma/cells of the immune 
system
Innate immunity is the body’s immediate response to an infection. It is a non-
specific response, meaning that the same response is mounted to a large number of 
different pathogens. When activated, the innate response is often seen as an inflam-
matory response. Inflammation is the body’s response to injury or tissue damage.
Rhinosinusitis
4
Phagocytic cells are a part of the innate immune system and consist of poly-
morphonuclear cells, monocytes-macrophages, and eosinophils. Neutrophils and 
monocytes are normally found circulating in the bloodstream and are recruited 
to sites of infection by the process of extravasation. Receptors on the phagocyte 
interact with ligands on vascular endothelium, and the cells attach, arrest, and 
move from the circulation to the diseased tissue/lungs.
Monocytes, similar to neutrophils, can also migrate into the tissues and on doing 
so differentiate into macrophages. Macrophages have a number of key functions, 
including phagocytosis of infecting microbes, antigen presentation, and general 
removal of dying or damaged host cells [12].
3.1.1 Dendritic cells
These are bone marrow-derived cells, found in most tissues, including lymphoid 
tissues. Discovered by Ralph Steinman in the mid-1970s, dendritic cells are critical 
for the initiation of the immune response. They are so named, because of being 
covered with long membranous extensions that resemble the dendrites (extensions) 
of the nerve cells.
Dendritic cells capture antigens, e.g., pollen/animal dander, and process these 
antigens and then present them to naive T cells, initiating the adaptive immune 
response. The first stage of an immune response to any antigen is the processing and 
presentation of that antigen by antigen-presenting cells (APCs), e.g., dendritic cells.
3.1.2 Pattern recognition receptors (PRRs)
These are receptors of the innate immune system that recognize common 
molecular patterns on pathogen surfaces called pathogen-associated molecular 
patterns (PAMPS), structures that are conserved in broad classes of pathogens 
for their functional importance. Many of these receptors reside at the plasma 
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Airway dendritic cells (DC) are critical 
mediators of immune responses in the lung by 
virtue of their ability to sample, process, and 











The interleukins IL-25 and IL-33 and thymic 
stromal lymphopoietin are produced by 
injured epithelium and play critical roles in 
driving expression of Th2 cytokines
Table 1. 
Classification of the immune system, immune cells, and the inflammatory response in asthma summary of functions.
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membrane. They are proteins expressed, mainly, by cells of the innate immune 
system, such as dendritic cells, macrophages, monocytes, neutrophils, and 
epithelial cells.
i. One group of receptors, C-type lectins, recognizes certain sugar units that 
are typically located at the terminal position of carbohydrate chains on 
pathogen surfaces.
ii. Another group and one of the best-characterized signaling PRR families is 
the evolutionary conserved toll-like receptor system in mammals, named 
after a homologous receptor system used by the Drosophila fruit fly for 
protection from infection. In humans, there are 10 expressed TLR genes in 
mice [13], their products forming homo- or heterodimers with other family 
members, thus increasing the repertoire for recognition. TLR4, for example, 
has been shown to be the receptor recognizing lipopolysaccharide (LPS) 
found on the surface of Gram-negative bacteria such as Escherichia coli but 
not present on mammalian cells. The effect of pathogen components binding 
to TLRs on innate immune cells is TLR activation, which initiates signaling 
into the immune cell and the increased expression of a large number of target 
genes. The genes involved depend on the pattern of TLRs engaged, but com-
mon outcomes include the increased production of inflammatory mediators 
such as cytokines and chemokines, enhanced phagocytosis (internalization 
and killing of the pathogen), upregulation of costimulatory molecules on 
the cell surface, cell migration, and, in the case of macrophages, increased 
processing and presentation of pathogen antigens to activate an adaptive 
immune response.
There are also three other families of receptors that sense PAMPS when patho-
gens arrive in the cytoplasm:
i. NOD-like receptors (NLRs): e.g., NOD1 and NOD2
ii. RIG-like helicases (RLHs): the cytoplasmic RNA-helicase, RIG-I, and related 
proteins act as virus receptors
iii. Cyclic GMP-AMP synthase (cGAS, cGAMP synthase): NB
Functions of NOD1 and NOD2 and cyclic GMP-AMP synthase:
• NLRs is an acronym that stands for NOD-like receptors. These are a large 
family of cytosolic proteins activated by intracellular PAMPS. NOD1 and 
NOD2 recognize important PAMPS, e.g., muramyl dipeptides produced 
during the synthesis or degradation of either intracellular or extracellular 
bacteria.
• cGMP-AMP (cGAMP) synthase (cGAS) is a cytosolic DNA sensor that acti-
vates innate immune responses.
3.1.3 Mast cells
A large granule-rich cell found in the connective tissue of the body, most 
abundantly in the submucosal tissues and the dermis. The granules store bioactive 
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molecules including the vasoactive amine, which are released on mast cell-activated 
and are involved in the pathogenesis of bronchoconstriction in asthmatic airways 
[13, 14].
3.1.4 Eosinophils
A type of white blood cell containing granules that stain with eosin and is an 
effector cell in asthma as well as produces cytokines, e.g., IL-5 [15, 16]. In the 
airway of asthmatic patients, eosinophil-derived mediators of inflammation, 
including eosinophil-derived neurotoxin (EDN), major basic protein (MBP), and 
lysophospholipase (LPL), are toxic to the respiratory epithelium contributing to the 
immune pathogenesis of asthma in both children and adults [16].
3.1.5 Basophils
A type of white blood cell containing granules that stain with basic dyes. 
Basophils are non-phagocytic granulocytes. In response to binding of circulat-
ing antibodies, basophils release their contents including histamine which cause 
smooth muscle contraction in asthmatic airways as well as increasing blood perme-
ability which may account for edema of the airways in asthma and inflammation 
[17, 18]. Basophils and mast cells release mediators of immediate hypersensitivity, 
e.g., histamine. Basophils are present in the blood stream, whereas mast cells are 
present only in the tissue.
3.1.6 Natural killer cells
A type of innate lymphoid cell (ILC) that is important in innate immunity 
to viruses and other intracellular pathogens and in antibody-dependent cellular 
cytotoxicity (ADCC) hypersensitivity reacyions.
They do not express antigen receptors and are considered part of the innate 
immune system, despite being lymphoid cells [19, 20].
3.1.7 NKT cells
Is another type of cell in the lymphoid lineage that shares features with both 
conventional T lymphocytes and NK cells like T cells; NKT cells have T-cell recep-
tors (TCRs) and some express CD4. Unlike most T cells, however, the TCRs of NKT 
cells are not very diverse and recognize specific lipids and glycolipids presented by 
a molecule related to the major histocompatibility complex (MHC) proteins called 
CD1.
Like their innate immune counterparts, NK cells, NKT cells have antibody 
receptors.
NKT cells are considered as a cell subset belonging to the innate immune system 
with the capacity to amplify adaptive immune responses in asthma [7–9, 21].
Defining the roles of thymic stromal lymphopoietin, IL-25, and IL-3 in human 
asthma:
IL-25, IL-33, and TLSP are epithelial-derived cytokines and have been identified 
as having an important role in asthma pathogenesis. These cytokines have been 
described as epithelial-derived alarmins that activate and potentiate the innate and 
humoral arms of the immune system in the presence of actual or perceived damage.
TSLP is increased in asthmatic airways, mast cells and in the lungs is produced 
mainly by airway epithelial cells. In addition, these three cytokines can gener-
ate a H2 cytokine profile independent of the adaptive immune system. TSLP is a 
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TH2-promoting cytokine that significantly contributes to the immune pathogenesis 
of asthma [22–24].
3.1.8 IL-33
Interleukin-33 (IL-33), which belongs to the larger family of damage-associated 
molecular pattern molecules, has been considered as an “alarmin” [22–24]. It is 
released to alert the immune system by first-line cells, such as tissue epithelial cells.
3.1.9 IL-C2
Innate lymphoid cells are a group of lymphoid cells with a recently recognized 
role as regulators of innate immunity, inflammation, and tissue repair at the barrier 
surfaces. They are a lymphoid subclass characterized by the lack of either B- or 
T-cell receptors but retain cytotoxic or immunomodulatory capacity [22–24].
The innate defense system contains cells that look just like B or T lymphocytes 
under the microscope, yet express neither B- nor T-cell receptors. These cells are 
known as innate lymphoid cells.
Innate lymphoid cells are classified into three groups based on their transcrip-
tion factors and cytokine production patterns, which mirror helper T-cell subsets. 
Unlike T cells and B cells, ILCs do not have antigen receptors. They respond to 
innate factors released by the bronchial epithelium, such as cytokines and alarmins, 
including IL-33, IL-25, and thymic stromal lymphopoietin [22–24]. ILCs produce 
multiple pro-inflammatory and immune regulatory cytokines for the induction and 
regulation of inflammation.
3.1.10 CC16 club cells/Clara cells
Clara cells are non-ciliated, non-mucous, secretory cells in respiratory epithe-
lium. These epithelial cells secrete several distinctive proteins, including Clara cell 
10-kDa secretory protein (CCSP). Clara cells are most predominant in the terminal 
and respiratory bronchioles of humans.
Club cells, also known as bronchiolar exocrine cells and originally known as 
Clara cells, are dome-shaped cells with short microvilli, found in the small airways 
(bronchioles) of the lungs.
Of recent Clara cells (CC16) have re-emerged in the immune pathogenesis of 
Asthma [25].
3.2 The adaptive inflammatory cells
T-cell responses to antigens consist of a combination of pro-inflammatory 
(effector) and anti-inflammatory (regulatory) cells.
• Lymphocytes differentiate into separate lineages. The B lymphocytes secrete 
antibodies.
The T lymphocytes operate in a supervising role to mediate cellular and humoral 
responses. Antigen presentation describes a vital immune process which is essential 
for T-cell immune response triggering immunity. B and T lymphocytes produce and 
express specific receptors for antigens. Collectively, the functions of the T and B 
cells encompass an entity called the adaptive immune system.
T-helper lymphocytes conventionally are TH1 and TH2 cells. TH1 cells produce 
cytokines that downregulate the atopic response. In those who are genetically 
susceptible to developing asthma, antigen presentation to T-helper cells leads to a 
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TH2 response, pro-inflammatory cytokines, and upregulation of airway inflamma-
tion of asthma by enhancing immunoglobulin E synthesis, eosinophils, and mast 
cell activation/function.
3.2.1 TREG cells
TREG cells, a type of T-helper lymphocytes, bind interleukins 2 via the CD25 
and CD45RB receptors to signal suppression of the immune system. This is essen-
tial in arresting inflammatory allergic responses such as in asthma and allergic 
rhinitis. In addition, naive T lymphocytes are induced to synthesize FoxP3 which 
acts as a transcription factor for the cytokines involved in the TREG-mediated 
cascade. In particular, transforming growth factor-β (TGF-β) and interleukin-10 
are the main cytokines implicated in the TREG-mediated suppression of inflam-
matory allergic responses [26, 27]. Thus, TREG cells are critical in the autoregula-
tion of allergic inflammatory reactions by slowing the pathological effects of the 
Th2 type immune responses in bronchial hyper-reactivity and inflammation in 
asthma [26–28].
3.3 The respiratory airway cells/mucosal immunology
There are several cells in the epithelium of the lower respiratory tract. The upper 
part includes support cells (basement), mucous-secreting cells, and the cilia, to aid 
the expulsion of mucous. However, Clara cells and cilia dominate in the lower parts 
of the respiratory system [29, 30].
Some of these cells are involved in inflammatory allergic responses in asthma. 
For instance, in asthma the goblet cells, i.e., mucous-secreting cells, increased the 
number of goblet cells as part of airway remodeling. The mucus (i.e., a complex 
solution of lipids and proteins in the airways) aggravates the immunopathology 
of asthma. The function of mucous is to trap inhaled particles/allergen and the 
interaction with the tips of beating cilia and remove particles/allergen from the 
airways, a process termed mucociliary clearance [31]. Other cells such as the neu-
roendocrine cells are not directly involved in the immunopathogenesis of asthma. 
Neuroendocrine cells (i.e., small round cells with dark staining nucleus and clear 
cytoplasm) contain characteristic granules and secrete hormones and peptides such 
as serotonin.
In particular, lymphoid tissues are mainly found in the bronchial. Thus during 
an asthmatic attack, the airways are remodeled (i.e., bronchial thermoplasty), 
which is characterized by swelling, cellular infiltration, and hyperplasia of smooth 
muscles and goblet cells [7–9].
The adaptation (i.e., hypertrophy, metaplasia, fibrosis, and hyperplasia) of 
the epithelial airways and smooth muscle cells to allergic and/or noxious stimuli 
compromises the structure and function of the airways [31, 32].
Indeed, the epithelial cells are important in providing rapid response to counter 
allergens by secreting mucous and initiating the inflammation. This epithelium 
provides a barrier against the external environment and protects against infection 
from airborne pathogens. Defective barrier function or viral infection can lead to 
respiratory tract disease like asthma.
The first line of defense against invasion by potential pathogens is the thin layer 
of epithelium that covers mucosal surfaces including that of the upper and lower 
respiratory tract. The mucosal immune system has unique features including large 
size, uptake, and presentation of antigen and contains a large number of effector 
T lymphocytes. The circulation of lymphocytes within the mucosal immune system 
is controlled by tissue-specific adhesion molecules and chemokine receptors.
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The analysis of molecular markers of airway inflammation has provided promis-
ing and noninvasive techniques that facilitate the detection of disease phenotypes as 
well as measurement of therapeutic efficacy for asthma.
Current treatments for severe forms of asthma have been extended to the use 
of biological modifiers for the classical asthma endotypes (i.e., Th2 high and Th2 
low). Conventional immune modulators (omalizumab, mepolizumab, reslizumab, 
benralizumab, and dupilumab) used in the management of severe forms of asthma 
are for patients with asthma of the type Th2 high. The inflammatory in patients 
with TH2 high asthma is principally mediated by eosinophils reactions as well as 
type 2 cytokines (i.e., IL-4, IL-13, IL-5) produced by Th2 cells. The type 2 cytokines 
are in turn regulated by other interleukins, namely, IL-25 and IL-33, as well as 
TSLP [9, 10]. These mediators are upstream innate factors that drive IL-13 and IL-5 
production.
In contrast, TH2 low asthma is poorly described. Patients do not have eosino-
philia and other markers but have neutrophilia inflammation. This is mainly due to 
the activation of TH1 or 17 cells that release IFN and IL-17. These cells are specifi-
cally produced at mucosal surfaces and thus are important in airway inflammation. 
The role of ILCs, more specifically type 2 ILCs, in the pathogenesis of allergic 
airway diseases has been extensively investigated over the last decade. Chronic nasal 
inflammation may aggravate or lead to the development of other significant disor-
ders, including asthma, rhinosinusitis, and middle ear disease.
3.3.1 Allergic rhinitis and mediators of the inflammatory response
Sensitization is initiated in nasal tissues when antigen that is deposited on the 
nasal mucosa is engulfed by antigen-presenting cells—macrophages, dendritic cells, 
Langerhans cells—and partially degraded within their phagolysosomes into anti-
genic peptides. These peptides are then externalized on the surfaces of APCs and 
are presented to naive CD4+ T lymphocytes. The interaction of T-helper lympho-
cytes is activated by presentation of an allergen via the MHC class II receptor on 
macrophages and other cells [32–34].
In patients with allergic rhinitis, allergen-triggered early and late responses 
are mediated by a series of inflammatory cells. Within minutes of contact with 
allergen, IgE-sensitized mast cells degranulate, releasing both preformed and 
newly synthesized mediators. Immunologic processes in both nasal and bronchial 
tissues involve TH2 lymphocytes and eosinophils. Eosinophils are the predominant 
cell in the chronic inflammatory process characteristic of the late-phase allergic 
response. Eosinophils release an array of pro-inflammatory mediators, including 
cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic 
protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13. 
Neuropeptides also appear to contribute to the pathophysiology of allergic rhinitis 
symptoms.
3.3.2 Allergen exposure
The respiratory tract is an important route of allergen entry. Several people react 
to airborne allergens with an IgE-mediated reaction, resulting from the deposition 
of mucosal mast cells beneath the nasal epithelium by allergens such as pollen that 
when they contact the epithelium, they release their soluble protein content, which 
is rich in eosinophils and allergic rhinitis characterized by intense itching, sneezing, 
nasal blockage, and irritation of the nasal mucosa due to histamine release.
In atopic-related allergic rhinitis, the hypersensitivity mediated via IgE, mast 
cells, and lymphocytes is inherited. The continued exposure of allergens initiates 
Rhinosinusitis
10
the inflammatory process via the APC, lymphocytes, and cytokine cascades (i.e., 
IL-3, IL-4, and IL-5). Until, then the immune system is not yet sensitized to the 
allergen. Following sensitization, further exposures initiate the inflammatory/aller-
gic response and clinical presentation of allergic rhinitis.
3.3.3 United airway hypothesis/disease
Upper and lower airways are considered a unified morphological and func-
tional unit, and the connection existing between them has been observed for 
many years, both in health and in disease [35]. The respiratory system is inte-
grated, and thus the allergic diseases of the lower (i.e., asthma) and the upper 
respiratory tract (allergic rhinitis) have similar pathogenesis and should be 
considered as one. Indeed, precious studies have shown an overlap in the clinical 
presentation of these two diseases where patients with allergic rhinitis are at risk 
for asthma.
4. Conclusions
Asthma and allergic rhinitis are a complex heterogeneous group of airway dis-
eases that affects both children and adults worldwide. Through the use of molecular 
and cellular immunology, conceptual shifts have been made in the understanding 
of these diseases involving both innate and adaptive immunity as well examination 
of airway epithelial changes that occur with asthma, evolving into personalized-
targeted therapy for asthma in view of these mechanisms. Allergic rhinitis is the 
most common of all atopic diseases, and although it can develop at any age, most 
patients report the onset of symptoms before 30 years of age, making it the most 
common chronic disorder in children.
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